BCL2 and cancer: For example, Navitoclax (ABT263), a dual inhibitor of Bcl-2 and Bcl-xL, and Venetoclax (ABT199), a selective Bcl-2 inhibitor, were initially designed as small molecule inhibitors targeting Bcl-2 family proteins in cancer therapeutics and have been investigated for their ability to induce cell death in HIV-infected cells [19,20,21].